ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. We engage pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes.
Notably, our professional assistance is always custom-tailored to your R&D Chemistry, Biology and Clinical needs. We pride ourselves on being one of the industry's most experienced CROs that deal with every aspect of both early and clinical development of oncology-, CNS-, metabolic-, anti-inflammatory and antiviral therapies. Our track record spans successful and timely delivery of discovery libraries, target-biased compound sets reflective of modern trends in Chemical Biology, pathway analysis, in vitro/ex vivo and in vivo assay development and implementation, a multitude of modern drug discovery and evaluation platforms all aimed at accelerated R&D. The integrated Discovery outSource solutions cover all disciplines needed to bring a project from target ID to Phase II clinical candidate.
Representative examples (for a complete list of services, please visit us at www.chemdiv.com) include protein engineering, production, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK and multiple in vivo efficacy/tox models. Proteomics and biomarker ID capabilities will be added to our portfolio in 2013. Our collaborators range from Pharma/Biotech to academia, foundations and screening centers: every request or project gets equal attention of our expert team.